{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:06:20Z","timestamp":1791839180331,"version":"4.3.4"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec id=\"ab-ooi240037-4\"><jats:title>Importance<\/jats:title><jats:p>For patients treated with immune checkpoint inhibitors (ICIs), recent data suggest that obesity has a beneficial effect on survival outcomes in various cancer types. Reports on this association in head and neck cancer are limited.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi240037-5\"><jats:title>Objectives<\/jats:title><jats:p>To compare overall survival (OS) to 5 years and functional outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with ICIs based on pretreatment body mass index (BMI).<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi240037-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This retrospective population-based cohort study used data obtained from the TriNetX Global Collaborative Network database to identify patients with HNSCC who received ICI treatment between January 1, 2012, and December 31, 2023, resulting in a total of 166 patients (83 with BMI of 20.0-24.9 [normal BMI] and 83 with BMI of \u226530.0 [obesity BMI]) after propensity score matching (PSM) for pretreatment medical comorbidities and oncologic staging.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi240037-7\"><jats:title>Exposure<\/jats:title><jats:p>Normal BMI vs obesity BMI.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi240037-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Overall survival and functional outcomes (dysphagia, tracheostomy dependence, and gastrostomy tube dependence) were measured to 5 years after ICI treatment and compared between patients with obesity BMI  and normal BMI.  Additional analyses compared OS and functional outcomes in the cohort with normal BMI and cohorts with overweight BMI (25.0-29.9) and underweight BMI (&amp;amp;lt;20.0).<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi240037-9\"><jats:title>Results<\/jats:title><jats:p>Among the 166 patients included in the PSM analysis (112 men [67.1%]; mean [SD] age, 62.9 [15.4] years), obesity BMI was associated with significantly improved OS at 6 months (hazard ratio [HR], 0.54 [95% CI, 0.31-0.96]), 3 years (HR, 0.56 [95% CI, 0.38-0.83]), and 5 years (HR, 0.62 [95% CI, 0.44-0.86]) after ICI treatment, compared with patients with normal BMI. Obesity BMI was also associated with decreased risk of gastrostomy tube dependence at 6 months (odds ratio [OR], 0.41 [95% CI, 0.21-0.80]), 1 year (OR, 0.41 [95% CI, 0.21-0.78]), 3 years (OR, 0.35 [95% CI, 0.18-0.65]), and 5 years (OR, 0.34 [95% CI, 0.18-0.65]). Obesity was also associated with decreased risk for tracheostomy dependence at 1 year (OR, 0.52 [95% CI, 0.28-0.90]), 3 years (OR, 0.45 [95% CI, 0.45-0.90]), and 5 years (OR, 0.45 [95% CI, 0.45-0.90]). There were no differences in rates of dysphagia or immune-related adverse events between cohorts at any points.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi240037-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Using population-level data for patients with HNSCC treated with ICIs, these results suggest that having obesity was associated with improved 6-month, 3-year, and 5-year OS compared with having normal BMI. Additionally, obesity was associated with decreased gastrostomy and tracheostomy tube dependence compared with normal BMI. Further investigation is required to understand the mechanism of these findings.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoto.2024.1568","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T15:08:53Z","timestamp":1720019333000},"page":"688","source":"Crossref","is-referenced-by-count":14,"title":["Obesity and Survival After Immune Checkpoint Inhibition for Head and Neck Squamous Cell Carcinoma"],"prefix":"10.1001","volume":"150","author":[{"given":"Eric V.","family":"Mastrolonardo","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Llerena","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Nunes","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace K.","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dev","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Bridgham","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramez","family":"Philips","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Cognetti","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Luginbuhl","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Curry","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10212","key":"ooi240037r1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"ooi240037r2","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck.","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"ooi240037r3","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer\u2014viewpoint of the IARC Working Group.","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"issue":"17","key":"ooi240037r4","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.","volume":"348","author":"Calle","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"ooi240037r5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1097\/JTO.0b013e31829cf942","article-title":"Body mass index and its association with clinical outcomes for advanced non\u2013small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials.","volume":"8","author":"Dahlberg","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"13","key":"ooi240037r6","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-18-3661","article-title":"Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab.","volume":"25","author":"De Giorgi","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"ooi240037r7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30239-0","article-title":"Body-mass index and metastatic melanoma outcomes.","volume":"19","author":"Wen","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"ooi240037r8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10552-014-0490-3","article-title":"Obesity and head and neck cancer risk and survival by human papillomavirus serology.","volume":"26","author":"Tan","year":"2015","journal-title":"Cancer Causes Control"},{"key":"ooi240037r9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.oraloncology.2018.05.027","article-title":"Impact of obesity on outcomes for patients with head and neck cancer.","volume":"83","author":"Hicks","year":"2018","journal-title":"Oral Oncol"},{"issue":"1","key":"ooi240037r10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"issue":"3","key":"ooi240037r11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"ooi240037r12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0448","article-title":"Outcomes among patients with or without obesity and with cancer following treatment with immune checkpoint blockade.","volume":"5","author":"Yoo","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"8","key":"ooi240037r13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005226","article-title":"Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study.","volume":"10","author":"Lee","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"6","key":"ooi240037r14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.20513","article-title":"Association of body mass index with outcomes among patients with head and neck cancer treated with chemoradiotherapy.","volume":"6","author":"Ma","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"ooi240037r15","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/cam4.v12.3","article-title":"The association between body mass index and efficacy of pembrolizumab as second-line therapy in patients with recurrent\/metastatic head and neck squamous cell carcinoma.","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med"},{"issue":"3","key":"ooi240037r16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/JLB.5RI1017-401RR","article-title":"Obesity as an immune-modifying factor in cancer immunotherapy.","volume":"104","author":"Canter","year":"2018","journal-title":"J Leukoc Biol"},{"issue":"1","key":"ooi240037r17","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltac015","article-title":"Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy.","volume":"2","author":"Pasquarelli-do-Nascimento","year":"2022","journal-title":"Immunother Adv"},{"issue":"9","key":"ooi240037r18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11912-016-0539-4","article-title":"The obesity paradox in cancer: a review.","volume":"18","author":"Lennon","year":"2016","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"ooi240037r19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12929-022-00796-0","article-title":"The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy.","volume":"29","author":"Assump\u00e7\u00e3o","year":"2022","journal-title":"J Biomed Sci"},{"issue":"7","key":"ooi240037r20","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.cell.2020.11.009","article-title":"Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity.","volume":"183","author":"Ringel","year":"2020","journal-title":"Cell"},{"issue":"8","key":"ooi240037r21","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1158\/1055-9965.EPI-12-0485","article-title":"The role of obesity in cancer survival and recurrence.","volume":"21","author":"Demark-Wahnefried","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"ooi240037r22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"ooi240037r23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors.","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ooi240037r24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canep.2016.01.003","article-title":"Obesity and cancer: an update of the global impact.","volume":"41","author":"Arnold","year":"2016","journal-title":"Cancer Epidemiol"},{"issue":"4","key":"ooi240037r25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s13244-015-0414-0","article-title":"Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome.","volume":"6","author":"Yip","year":"2015","journal-title":"Insights Imaging"},{"issue":"5","key":"ooi240037r26","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.cct.2011.05.006","article-title":"Are propensity scores really superior to standard multivariable analysis?","volume":"32","author":"Biondi-Zoccai","year":"2011","journal-title":"Contemp Clin Trials"},{"key":"ooi240037r27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/COPD","article-title":"Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching.","volume":"7","author":"Roberts","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"ooi240037r28","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1089\/sur.2020.425","article-title":"Advanced statistics: multiple logistic regression, Cox proportional hazards, and propensity scores.","volume":"22","author":"Cioci","year":"2021","journal-title":"Surg Infect (Larchmt)"}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2820681\/jamaotolaryngology_mastrolonardo_2024_oi_240037_1722952893.17862.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T15:08:34Z","timestamp":1723129714000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2820681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2024.1568","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}